Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

My take away from the comment about 2 drug combo w

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154730
(Total Views: 438)
Posted On: 08/21/2019 10:33:12 AM
Posted By: gestalt2
Re: ohm20 #6419
My take away from the comment about 2 drug combo was they are trying to make a partnership with a BP that has an existing HIV pipline easier to digest. Any BP that partners/buys cytodyn has to explain to their shareholders why the investment in their current HIV pipline is now obsolete, which is not easy. It is also not going to be easy to explain how they let cytodyn get all the way through trials, approval and be on the market with their product and have there revenue take a huge hit without partnering/buyout when it was so cheap for so long. This is cytodyn building what the deal could look like with a 2 drug platform instead of the our product is better than yours and we will crush you type attitude.

Cytolin and Leronlimab were both originally to be approved as monotherapy drugs. The easiest and quickest path was originally to get them approved as a "holiday" drug so patients had an option to take a break from their normal drugs. The FDA is who required the combo trial approval before anything else. I think this was purely so they could compare apples to apples - all other HIV drugs are approved in combination so Leronlimab also had to. Ultimately this combo trial process will pay off because the mono trial does not have to prove itself in terms of safety or efficacy. In my opinion, the reason Nader talks of the mono trial as if getting the protocol approved is the most important milestone rather than the actual trial data and approval is because he knows that partnerships and buyouts happen before trials will be finished. The industry already knows Leronlimab works as a mono drug, the pivotal trial data will be no surprise. Getting the FDA to let them go for it shows that the FDA is ready for a mono drug and Cytodyn has it. BP must act once they know the FDA is green lighting this. Any concern about how long or how many patients are required does not matter much, just that the protocol is agreed on.

It is hard to really get the direction of cytodyn's grand plan. On one hand they are trying to make the combo approval more palletable to BP, on the other they are very close to showing their drug will make many existing drugs and piplines obsolete. My impression is that the message is formed as the deals and opportunities surface. I feel the whole "go at it alone" statements are purely to show they don't need a BP deal, even though they would rather have one.


(5)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us